---
layout: post
title: New Drug Approvals 2011 - Pt. XXI Rivaroxaban (XareltoTM)
date: '2011-07-05T03:38:00.006+01:00'
author: Ben
tags:
- 2011 New Drugs
- Black Box Warning Drugs
modified_time: '2012-01-04T09:32:26.705Z'
thumbnail: http://2.bp.blogspot.com/-QHYz81GFMm4/ThKpt9VqaAI/AAAAAAAABOM/FBG-tjjpbtc/s72-c/images.jpeg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-7410033924486566009
blogger_orig_url: http://chembl.blogspot.com/2011/07/new-drug-approvals-2011-pt-xxi.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-QHYz81GFMm4/ThKpt9VqaAI/AAAAAAAABOM/FBG-tjjpbtc/s1600/images.jpeg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://2.bp.blogspot.com/-QHYz81GFMm4/ThKpt9VqaAI/AAAAAAAABOM/FBG-tjjpbtc/s1600/images.jpeg" /></a></div>
<div style="text-align: center;">
<br /></div>
<br />
<br />
<center face="arial">  <img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,1,1,0,0,1,0,1" width="400" /></center><center face="arial"><br />
</center> <br />
<div style="text-align: center;">
<b>ATC code:</b>&nbsp;<a href="http://www.whocc.no/atc_ddd_index/?code=B01AX06">B01AX06</a> <br />
<br /></div>
<div style="text-align: justify;">
<span class="Apple-style-span" style="font-family: inherit;">On July 1st, FDA approved Rivaroxaban (trade name:&nbsp;</span><a href="http://www.trademarkia.com/xarelto-rivaroxaban-tablets-77794161.html"><span class="Apple-style-span" style="font-family: inherit;">Xarelto</span></a><span class="Apple-style-span" style="font-family: inherit;">, Research code: BA-59-7939, NDA 022406), an </span><a href="http://en.wikipedia.org/wiki/Anticoagulant"><span class="Apple-style-span" style="font-family: inherit;">anti-coagulant</span></a><span class="Apple-style-span" style="font-family: inherit;"> to prevent </span><a href="http://en.wikipedia.org/wiki/Deep_vein_thrombosis"><span class="Apple-style-span" style="font-family: inherit;">deep vein thrombosis</span></a><span class="Apple-style-span" style="font-family: inherit;"> (DVT) in patients with </span><a href="http://en.wikipedia.org/wiki/Knee_replacement"><span class="Apple-style-span" style="font-family: inherit;">knee</span></a><span class="Apple-style-span" style="font-family: inherit;"> or </span><a href="http://en.wikipedia.org/wiki/Hip_replacement"><span class="Apple-style-span" style="font-family: inherit;">hip</span></a><span class="Apple-style-span" style="font-family: inherit;"> replacement surgery. Rivaroxaban is the first orally applied </span><a href="http://en.wikipedia.org/wiki/Direct_factor_Xa_inhibitor"><span class="Apple-style-span" style="font-family: inherit;">direct inhibitor</span></a><span class="Apple-style-span" style="font-family: inherit;"> of </span><a href="http://en.wikipedia.org/wiki/Factor_xa"><span class="Apple-style-span" style="font-family: inherit;">Factor Xa</span></a><span class="Apple-style-span" style="font-family: inherit;"> (FXa), a key regulatory of the </span><a href="http://en.wikipedia.org/wiki/Coagulation"><span class="Apple-style-span" style="font-family: inherit;">coagulation cascade</span></a><span class="Apple-style-span" style="font-family: inherit;">. In DVT, a blood clot is formed which can dislodge and travel to the lungs, causing </span><a href="http://en.wikipedia.org/wiki/Pulmonary_embolism"><span class="Apple-style-span" style="font-family: inherit;">pulmonary embolism</span></a><span class="Apple-style-span" style="font-family: inherit;"> which can be potentially fatal.</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: inherit;">Factor Xa (EC number </span><a href="http://enzyme.expasy.org/EC/3.4.21.6"><span class="Apple-style-span" style="font-family: inherit;">3.4.21.6</span></a><span class="Apple-style-span" style="font-family: inherit;">, UniProt ID </span><a href="http://www.uniprot.org/uniprot/P00742"><span class="Apple-style-span" style="font-family: inherit;">P00742</span></a><span class="Apple-style-span" style="font-family: inherit;">, OMIM </span><a href="http://www.omim.org/entry/613872"><span class="Apple-style-span" style="font-family: inherit;">613872</span></a><span class="Apple-style-span" style="font-family: inherit;">) is a serine </span><a href="http://en.wikipedia.org/wiki/Serine_protease"><span class="Apple-style-span" style="font-family: inherit;">endopeptidase</span></a><span class="Apple-style-span" style="font-family: inherit;">, cleaving prothrombin into its active form, </span><a href="http://en.wikipedia.org/wiki/Thrombin"><span class="Apple-style-span" style="font-family: inherit;">thrombin</span></a><span class="Apple-style-span" style="font-family: inherit;">, which then activates further downstream factors which ultimately lead to </span><a href="http://en.wikipedia.org/wiki/Platelet_activation#Platelet_activation"><span class="Apple-style-span" style="font-family: inherit;">platelet activation</span></a><span class="Apple-style-span" style="font-family: inherit;"> and </span><a href="http://en.wikipedia.org/wiki/Fibrin"><span class="Apple-style-span" style="font-family: inherit;">fibrin</span></a><span class="Apple-style-span" style="font-family: inherit;"> formation, clotting the damaged blood vessels.  The sequence of Factor X is </span><br />
<br />
<div style="text-align: left;">
<pre>&gt;Factor X
MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE
TCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN
CELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR
KRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTR<span style="font-weight: bold;">IVGGQE</span>
<span style="font-weight: bold;">CKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE</span>
<span style="font-weight: bold;">AVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI</span>
<span style="font-weight: bold;">VSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG</span>
<span style="font-weight: bold;">GPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE</span>
<span style="font-weight: bold;">VITSSPLK</span>
</pre>
</div>
<br />
Factor X itself is synthesized as an inactive precursor, and is further processed into a mature form, consisting of a light and an "activated" heavy chain (=FXa, <a href="http://www.uniprot.org/blast/?about=P00742[235-488]">residues 235-488</a>, bold in the above sequence, carrying a trypsin-like domain, Pfam <a href="http://pfam.sanger.ac.uk/family?acc=PF00089">PF00089</a>) (green and red in the below picture, respectively). There is a plethora of experimentally solved structures available for FXa, and also a <span style="font-style: italic;">holo</span>structure of FXa in complex with Rivaroxaban, PDBe:<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/2w26/summary.html">2w26</a>.<br />
<br />
&nbsp;  <a href="http://2.bp.blogspot.com/-57Y8oTEMubM/ThHcXDceBlI/AAAAAAAAADE/5prsN9pcu9g/s1600/full1.png"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5625519698182276690" src="http://2.bp.blogspot.com/-57Y8oTEMubM/ThHcXDceBlI/AAAAAAAAADE/5prsN9pcu9g/s400/full1.png" style="cursor: pointer; display: block; height: 300px; margin: 0px auto 10px; text-align: center; width: 400px;" /></a> <br />
<div style="text-align: center;">
<a href="http://4.bp.blogspot.com/-IWSFr7xs2eM/ThHU22DpzHI/AAAAAAAAAC8/wtBVYkkecyc/s1600/full1.png"> </a></div>
Rivaroxaban (ChEMBL ID <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL198362">198362</a>, ATC code <a href="http://www.whocc.no/atc_ddd_index/?code=B01AX06">B01AX06</a>, PubChem CID <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6433119">6433119</a>) has molecular weight of 435.9 Da, an ALogP of 1.8, 5 rotatable bonds, 6 hydrogen bond acceptors, 1 hydrogen bond donor, and is thus fully Rule-of-Five compliant. It is dosed as a pure <span style="font-style: italic;">(S)</span>-enantiomer.  Canonical Smiles, Smiles=Clc1ccc(s1)C(=O)NC[C@H]2CN(C(=O)O2)c3ccc(cc3)N4CCOCC4=O, Standard InChi, InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1.  Rivaroxaban <a href="https://www.ebi.ac.uk/chembldb/index.php/doc/inspect/CHEMBL1140410">is known</a> to have a sub-nanomolar (0.7 nM) IC<sub>50</sub> to the active site of human FXa.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-DqbrAqKetZE/ThJ4zOeW07I/AAAAAAAABOE/qZh0s2c4sis/s1600/250px-Rivaroxaban_structure.svg.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://1.bp.blogspot.com/-DqbrAqKetZE/ThJ4zOeW07I/AAAAAAAABOE/qZh0s2c4sis/s1600/250px-Rivaroxaban_structure.svg.png" /></a></div>
<br />
Xarelto is administered orally as a 10 mg tablet once daily for 12 or 35 days (after knee/hip replacement surgery, respectively), yielding ~23 umol of active substance per single dose. Most relevant risks connected to Xarelto treatment are serious and fatal bleeding.<br />
<br />
It has been given a boxed warning for <a href="http://en.wikipedia.org/wiki/Epidural_hematoma">spinal/epidural hematoma</a> in surgical settings. It has not been tested in pregnant women, nursing mothers, or pediatric settings; majority of participants in clinical trials were 65 years and over, and the efficacy of Xarelto in the elderly was found to be similar to that seen in younger patients. The effect of Xarelto lasts 8-12 hours, but FXa activity stays depleted during 24 hours, so a once-daily dose is sufficient.<br />
<br />
It has high (80-100%) bioactivity and is rapidly absorbed, reaching C<sub>max</sub> at 2 to 4 hours. Its volume is distribution is V<sub>ss</sub>=50 L. Little metabolism is observed for rivaroxaban, with the majority of the dose excreted unchanged.<br />
<br />
The USAN/INN&nbsp;<a href="http://druginfo.nlm.nih.gov/drugportal/jsp/drugportal/DrugNameGenericStems.jsp">name stem</a>, -xaban of rivaroxaban, designates a FXa inhibitor. Alternative anticoagulants, inhibiting FXa indirectly, include <a href="http://en.wikipedia.org/wiki/Heparin">Heparin</a> (ChEMBL ID <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL526514">526514</a>), an activator of <a href="http://en.wikipedia.org/wiki/Antithrombin">Antithrombin</a>, which itself is a FXa inactivator;  <a href="http://en.wikipedia.org/wiki/Warfarin">Warfarin</a> (ChEMBL ID <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1464">1464</a>), a <a href="http://en.wikipedia.org/wiki/Vitamin_K_antagonist">vitamin K antagonist</a>, <a href="http://en.wikipedia.org/wiki/Vitamin_k">vitamin K</a> being required for FXa biosynthesis. However, numerous other direct FXa inhibitors are currently being developed, e.g. <a href="http://en.wikipedia.org/wiki/Apixaban">Apixaban</a> (BMS-562247-01, ChEMBL ID <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL231779">231779</a>),&nbsp;<a href="http://en.wikipedia.org/wiki/Betrixaban">Betrixaban</a> (PRT-054021,&nbsp;ChEMBL ID <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL512351">512351</a>), Edobaxan (Du-176b), Eribaxaban (PD-348292), Fidexaban (ZK-807834), Otamixaban (XRP-0673), YM-150, YM-466, Letaxaban (TAK-442), and GW-813893.<br />
<br />
Xarelto has been developed by <a href="http://www.bayerpharma.com/">Bayer Schering AG</a>. In US, it will be marketed by <a href="http://www.janssenpharmaceuticalsinc.com/">Janssen Pharmaceuticals, Inc</a>.<br />
<br />
The product website can be found <a href="http://www.xarelto.com/">here</a>, the full prescribing information, <a href="http://www.janssenpharmaceuticalsinc.com/assets/xareltopi.pdf">here</a>. </div>